Exelixis and Roche partner for Phase Ib trial of cabozantinib+atezolizumab in solid tumours

Biopharmaceutical firm Exelixis has collaborated with healthcare firm Roche to evaluate the combination of cabozantinib and atezolizumab in a Phase Ib clinical trial to treat patients with metastatic solid tumours.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news